NBIX

#767
Neurocrine Biosciences Inc
129.6750 USD
+2.66%
版块: 医疗保健
基础: USD
利润货币: USD
日范围
129.4058
129.9250
年范围
122.1375
160.1800
日变化
+2.66%
每月变动
-0.56%
6个月变化
-10.57%
年变化
-10.57%
前一天收盘价
126.3200
开盘价
129.4700
买价
卖价
最低价
129.4058
High
129.9250
交易量
27
展开完整图表

Financials

概览 声明 统计
每季度 年度
  • Market Capitalization 13.0146 B
  • Employee 2 000
  • Founded 1992
  • CEO Kevin C. Gorman
  • Website www.neurocrine.com
  • Headquarter Delaware, United States
  • FIGI BBG000GJS7C1
  • Industry Technology
总收入
净利润
每股基本收益（基本 EPS）
总债务
自由现金流
现金及现金等价物
市盈率
30.37
市销率
5.08

Neurocrine Biosciences Inc

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine was approved in the US to treat adults with tardive dyskinesia. The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.

新闻